Late	late	O	O	O	O
,	,	O	O	O	O
late	late	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Cardiac	cardiac	O	DISEASE	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
is	is	O	O	O	O
a	a	O	O	O	O
major	major	O	O	O	O
complication	complication	O	O	O	O
which	which	O	O	O	O
limits	limits	O	O	O	O
the	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
adriamycin	adriamycin	CHEMICALS	O	OTHERS	I
as	as	O	O	O	O
a	a	O	O	O	O
chemotherapeutic	chemotherapeutic	O	O	O	O
agent	agent	O	O	O	O
.	.	O	O	O	O

Cardiomyopathy	cardiomyopathy	O	DISEASE	OTHERS	I
is	is	O	O	O	O
frequent	frequent	O	O	O	O
when	when	O	O	O	O
the	the	O	O	O	O
total	total	O	O	O	O
dose	dose	O	O	O	O
exceeds	exceeds	O	O	O	O
600	600	O	O	O	O
mg/m2	mg/m2	O	O	O	O
and	and	O	O	O	O
occurs	occurs	O	O	O	O
within	within	O	O	O	O
one	one	O	O	O	O
to	to	O	O	O	O
six	six	O	O	O	O
months	months	O	O	O	O
after	after	O	O	O	O
cessation	cessation	O	O	O	O
of	of	O	O	O	O
therapy	therapy	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
patient	patient	O	O	O	O
is	is	O	O	O	O
reported	reported	O	O	O	O
who	who	O	O	O	O
developed	developed	O	O	O	O
progressive	progressive	O	O	O	O
cardiomyopathy	cardiomyopathy	O	DISEASE	OTHERS	I
two	two	O	O	O	O
and	and	O	O	O	O
one-half	one-half	O	O	O	O
years	years	O	O	O	O
after	after	O	O	O	O
receiving	receiving	O	O	O	O
580	580	O	O	O	O
mg/m2	mg/m2	O	O	O	O
which	which	O	O	O	O
apparently	apparently	O	O	O	O
represents	represents	O	O	O	O
late	late	O	O	O	O
,	,	O	O	O	O
late	late	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

